Watson Gets To Investigate FTC Communications With FDA After Discovery Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal judge says the facts show "the strong possibility" that FTC tried to broker a deal between Watson and Apotex requiring Watson to give up its marketing exclusivity for generic Provigil.
You may also be interested in...
Watson CEO's Attorney Urges Court To Quash FTC Subpoena For His Testimony
Watson CEO Paul Bisaro claims FTC tried to force the company into deal with Apotex while FTC says it simply wants to know if Watson had a deal not to relinquish its market exclusivity.
Watson CEO Claims FTC Pressured Company To Allow Apotex To Market Generic Provigil
Watson CEO Paul Bisaro is fighting an FTC subpoena to testify in the commission's investigation of a reverse settlement agreement involving Cephalon's Provigil.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.